TYK Medicines, Inc. Class H AI Stock Analysis
Want to see HK:2410 full AI Analyst Report?
TYK Medicines, Inc. Class H (2410) AI Stock Analysis
TYK Medicines, Inc. Class H
(HKEX:2410)
The score is primarily constrained by zero revenue, substantial losses, and persistent cash burn. Moderate leverage and improved debt levels offer some resilience, while mixed technical momentum and weak valuation provide little additional support.
TYK Medicines, Inc. Class H (2410) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.42B
- Dividend Yield
- ―
- Average Volume (3M)
- 2.99M
- Price to Earnings (P/E)
- -6.2
- Beta (1Y)
- 1.80
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 184
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
TYK Medicines, Inc. Class H Business Overview & Revenue Model
Company Description
TYK Medicines, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, obtaining, advancing, and bringing to market innovative treatments for significant unmet needs in oncology. The company's primary drug candid...
TYK Medicines, Inc. Class H Financial Statement Overview
Summary
Financial performance is very weak: the company has zero TTM revenue, a net loss of about HKD 212 million, operating cash outflows of about HKD 213 million, and continued reliance on external funding. Moderate leverage and reduced debt provide limited support.
Income Statement
24NegativeBalance Sheet
52NeutralCash Flow
33Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0 | 0 | 107.00K | 0 | 44.24M |
| Gross Profit | 0 | -24.37M | 14.00K | -27.66M | 20.04M |
| EBITDA | -329.78M | -289.17M | -346.03M | -346.80M | -292.22M |
| Net Income | -212.49M | -292.01M | -386.95M | -382.43M | -310.99M |
Balance Sheet | |||||
| Total Assets | 768.55M | 780.07M | 915.69M | 573.14M | 558.36M |
| Cash, Cash Equivalents and Short-Term Investments | 201.96M | 367.44M | 460.46M | 192.83M | 243.49M |
| Total Debt | 149.63M | 152.81M | 176.85M | 1.33B | 82.33M |
| Total Liabilities | 507.79M | 493.13M | 443.13M | 1.45B | 1.06B |
| Stockholders Equity | 260.96M | 286.79M | 469.09M | -884.48M | -505.94M |
Cash Flow | |||||
| Free Cash Flow | -268.96M | -255.18M | -381.87M | -278.20M | -308.23M |
| Operating Cash Flow | -212.86M | -215.77M | -308.25M | -200.94M | -220.05M |
| Investing Cash Flow | 167.09M | 35.95M | -135.86M | 73.01M | -158.16M |
| Financing Cash Flow | 116.38M | 126.38M | 632.08M | 224.00M | 351.14M |
TYK Medicines, Inc. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2410, the sentiment is Neutral. The current price of 4.10 is above the 20-day moving average (MA) of 3.28, above the 50-day MA of 3.68, and below the 200-day MA of 7.77, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 63.59 is Neutral, neither overbought nor oversold. The STOCH value of 89.16 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2410.
TYK Medicines, Inc. Class H Peers Comparison
Overall Rating
HK:187370Outperform
HK:263370Outperform
HK:116748Neutral
HK:219745Neutral
HK:999645Neutral- HK:241041Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1873 | 70Outperform | HKD 2.71B | 13.47 | 4.45% | ― | 7.38% | 7.90% |
| HK:2633 | 70Outperform | HKD 1.75B | 6.09 | 13.26% | 9.83% | -0.47% | -0.40% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| HK:1167 | 48Neutral | HKD 3.78B | 6.29 | 47.76% | ― | 286.20% | ― |
| HK:2197 | 45Neutral | HKD 2.11B | 2.20 | -64.89% | ― | -99.15% | ― |
| HK:9996 | 45Neutral | HKD 2.69B | -16.19 | -7.65% | ― | 21.23% | 36.89% |
| HK:2410 | 41Neutral | HKD 1.47B | -6.21 | -77.60% | ― | ― | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2410 | TYK Medicines, Inc. Class H | 4.10 | -9.86 | -70.63% | |
| HK:9996 | Peijia Medical Ltd. | 4.03 | -2.11 | -34.45% | |
| HK:1167 | Jacobio Pharmaceuticals Group Co., Ltd. | 4.80 | -2.07 | -30.06% | |
| HK:1873 | Viva Biotech Holdings | 1.30 | -0.77 | -37.20% | |
| HK:2197 | Clover Biopharmaceuticals Ltd. | 1.71 | -0.90 | -34.48% | |
| HK:2633 | Jacobson Pharma Corporation Limited | 0.92 | -0.43 | -31.85% |
TYK Medicines, Inc. Class H Corporate Events
TYK Medicines Enters Conditional Huiyu Settlement
TYK Medicines entered a conditional settlement agreement with Huiyu on November 11, 2026, covering disputes over sales agency and related cooperation for TY-9591. Under the agreement, the company is to pay RMB300 million in two RMB150 million instalm...
TYK Medicines Reports Kardorisso Commercialization Update
On August 27, 2026, the company said Kardorisso had obtained conditional approval in China for first-line treatment of adults with locally advanced or metastatic NSCLC with CNS metastases and EGFR exon 19 deletion or exon 21 L858R mutation.The update...
TYK Medicines Shareholders Back Board Re-elections and Governance Changes
Shareholders of TYK Medicines, Inc. convened for the company’s second extraordinary general meeting of 2026 in Shanghai, where all directors attended either in person or electronically. The meeting complied with PRC Company Law and the firm’s Article...
TYK Medicines Calls October EGM to Refresh Board and Amend Articles
TYK Medicines, Inc. has called a second extraordinary general meeting for October 16, 2026 in Shanghai to vote on the re-election of several board members, including executive and non-executive directors, as well as independent non-executive director...
TYK Medicines Subscription Deal With Qilu Lapses but Collaboration Continues
TYK Medicines, Inc. announced that its subscription agreement with Qilu for the proposed issuance of 63,222,744 H shares has lapsed after certain conditions precedent were not fulfilled or waived by the revised long stop date of September 20, 2026. T...
TYK Medicines Sets Book Closure for 2026 Extraordinary General Meeting
TYK Medicines, Inc. has announced administrative arrangements for its 2026 second extraordinary general meeting, where shareholders will consider proposed amendments to the company’s articles of association and the re-election of directors. The move...
TYK Medicines CEO Boosts Stake With New H-Share Purchases
TYK Medicines, Inc. has disclosed that its chairman, executive director and chief executive officer, Dr. Wu Yusheng, has increased his stake in the company by acquiring 635,000 H shares on the open market between September 8 and 10, 2026, for about H...
TYK Medicines CEO Boosts Personal Stake While Upholding Public Float
TYK Medicines, Inc. has disclosed that its chairman, executive director and chief executive officer, Dr. Wu Yusheng, has increased his stake in the company through open-market share purchases funded by his personal resources. He has indicated that to...
TYK Medicines Wins Conditional China Nod for Next‑Generation Lung Cancer Drug
TYK Medicines, Inc. announced that its self‑developed Asandeutertinib Mesylate Tablets (TY‑9591), a next‑generation, irreversible and highly selective EGFR‑TKI, has received conditional marketing approval from China’s National Medical Products Admini...
TYK Medicines Extends Deadline for Major H-Share Subscription Deal
TYK Medicines, Inc., a PRC-incorporated biopharmaceutical company listed in Hong Kong under stock code 2410, is building its business around licensing and collaboration deals and the issuance of H shares under general mandates. The company’s strategy...
TYK Medicines Clarifies Board Structure and Committee Roles
TYK Medicines, Inc., a Hong Kong-listed pharmaceutical and biotechnology company incorporated in the People’s Republic of China, has structured its board with executive, non-executive and independent non-executive directors to support its research-dr...
TYK Medicines Narrows Interim Loss as Other Income Surges Despite Higher R&D Spend
TYK Medicines, Inc. reported an unaudited total comprehensive loss of RMB26.9 million for the six months ended June 30, 2026, a sharp improvement from a RMB114.1 million loss a year earlier, supported by a strong rise in other income and gains to RMB...
TYK Medicines reshapes board roles and plans director re-election
TYK Medicines, Inc. announced the resignation of non-executive director Dr. Jiang Mingyu, who stepped down effective August 17, 2026 to focus on other business endeavors, and confirmed there were no disputes or claims related to his departure. Concur...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026